IMCR

Immunocore Holdings plc

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1671927Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$400.0M

Net Income FY2025

$(36.0M)

EPS (Basic, as reported)

$-0.71

Net Margin FY2025

-8.9%

ROE FY2025

-9.3%

Total Equity

$381.0M

Shares Out

51M

Business description

Immunocore Holdings plc — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 4 → 400 +216.2% CAGR

Fiscal yearFY2021FY2022FY2023FY2024FY2025

Revenue4141239310400

Cost of revenue0(1)(1)(3)(5)

Research & development(100)(102)(164)(222)(275)

Selling, general & administrative(111)(123)(144)(156)(165)

Operating income(175)(52)(60)(70)(45)

Interest expense(6)(5)(5)(19)(12)

Interest & investment income04182616

Other income (expense), net0(2)(1)1420

Pre-tax income(180)(41)(61)(53)(19)

Income tax expense0(12)(6)(2)(16)

Net income(180)(53)(55)(51)(36)

EPS — basic($4.24)($1.15)($1.13)($1.02)($0.71)

EPS — diluted($4.24)($1.15)($1.13)($1.02)($0.71)

Shares outstanding — basic (M)4246495050

Shares outstanding — diluted (M)4246495050

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.